601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

NCT04922151 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Pathological Myopic Choroidal Neovascularization

Interventions

DRUG: 601
DRUG: Ranibizumab

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.